Clinical Trials Directory

Trials / Completed

CompletedNCT03189537

Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

Double Blind Randomised Placebo Controlled Trial for Evaluation of Efficacy and Safety of Ingavirin® for Post-exposure Profilaxis During Rise in the Incidence of Influenza and Other Acute Respiratory Viral Infections in Adults

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
400 (actual)
Sponsor
Valenta Pharm JSC · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study was to evaluate efficacy of prophylactic Ingavirin intake by people having contact with sick people infected with influenza and other acute respiratory viral infections

Detailed description

The study includes 7 days of treatment period and 30 days of follow-up, 37 days total. The participant was receiving Ingavirin or placebo for 7 days. Then during 30 days the participant was under supervision. Visits were performed at days 2-7 (every day) since inclusion and then every 5 days during follow-up period. Wherever during the study the participant developed symptoms of flu or other acute respiratory viral infection, the participant was taken for medical care to observe his condition, symptoms dynamics, lab tests, including laboratory verification of viral origin of the disease. Medical care was established for 10±2 days since symptoms. Everyday for 3 days and additional visits for 5±1 and 10±2 days of the disease. The patient had the required symptomatic treatment, additionally the patient could be institutionalised if necessary. Wherever the participant developed symptoms during treatment period, the patient was taken investigational drug on schedule.

Conditions

Interventions

TypeNameDescription
DRUGIngavirin (Imidazolyl Ethanamide Pentandioic Acid)Broad-spectrum antiviral agent
DRUGPlacebo oral capsulePlacebo capsule to match Ingavirin capsule

Timeline

Start date
2010-10-03
Primary completion
2011-04-19
Completion
2011-10-10
First posted
2017-06-16
Last updated
2017-06-16

Locations

2 sites across 1 country: Russia

Source: ClinicalTrials.gov record NCT03189537. Inclusion in this directory is not an endorsement.